WASHINGTON, D.C. -- The Food and Drug Administration (FDA) today announced that aLF Ventures of Salt Lake City has consulted with the agency about the company's plans to market lactoferrin, a component of an antimicrobial spray. This spray can be applied to uncooked beef carcasses to fight E.coli 0157:H7, an organism that can cause severe gastrointestinal disease in humans. FDA informed aLf Ventures today that it does not question their decision to market lactoferrin, an anti-microbial protein found in cow's milk and beef.
Although aLF Ventures was not required to seek approval from FDA before it marketed lactoferrin, aLF Ventures provided FDA scientific data supporting the firm's conclusion that lactoferrin is "generally recognized as safe" (GRAS) and safe for the general population as well as for individuals who are allergic to milk.
"Innovative technology is a critical building block in preserving the strong foundation of the U.S. food supply," said Dr. Lester Crawford, deputy commissioner of the FDA. "We must continue to encourage scientific research and new technology to maintain this nation's safe food supply."
A substance used in food can be GRAS if its safety has been established by generally available scientific data and information that lead qualified experts to conclude that the use of the ingredient is safe for its proposed use.
In its notice submitted to FDA, aLF Ventures noted that the amount of added lactoferrin that remains on the beef after spraying is comparable to the amount of lactoferrin that is naturally occurring in the beef.
aLF Ventures also submitted data to the U.S. Department of Agriculture (USDA) regarding the effectiveness of lactoferrin against E.coli 0157:H7. USDA is the agency responsible for addressing labeling issues with lactoferrin-treated beef.
Source: FDA
Genomic Surveillance A New Frontier in Health Care Outbreak Detection
November 27th 2024According to new research, genomic surveillance is transforming health care-associated infection detection by identifying outbreaks earlier, enabling faster interventions, improving patient outcomes, and reducing costs.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.